Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage III Melanoma
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17779 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Dong-Dong Jia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone and Soft-Tissue Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Ha…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pathogenic BRAF mutations drive constitutive MAPK pathway activation in melanoma, and targeted therapies with dabrafenib plus trametinib have improved outcomes in the adjuvant setting. However, the optimal duration of adjuvant therapy remains unclear. This retrospective study examined whether extending dabrafenib plus trametinib beyond 1 year offers additional clinical benefit in Chinese patients with resected Stage III melanoma.
Methods
Medical records from six centers were reviewed for adults with BRAF V600E/K–positive, completely resected Stage III melanoma who received at least 12 months of adjuvant dabrafenib plus trametinib. Patients were divided into a 1‐year therapy group and a more‐than‐1‐year therapy group. Relapse‐free survival (RFS) was the primary end point; adverse events were also assessed.
Results
Of the 122 patients included, 77 received more than 1 year of adjuvant therapy. The more‐than‐1‐year group experienced significantly better RFS (log‐rank p = 0.04), and longer therapy independently reduced recurrence risk in multivariate analysis (HR, 2.42; p = 0.035). Adverse event profiles did not differ between groups, and toxicity‐related treatment modifications occurred primarily within the first year.
Conclusions
Extending dabrafenib plus trametinib beyond 1 year may provide improved RFS without increasing toxicity. Further prospective trials are warranted to confirm the impact on overall survival and identify optimal patient subsets for prolonged therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone and Soft-Tissue Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.
- Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
- Department of Bone and Soft-Tissue Surgery, Hunan Cancer Hospital, Changsha, Hunan, China.
- Bone and Soft Tissue Oncology Department, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
- Department of Bone and Soft Tissue, Henan Cancer Hospital, Zhengzhou, Henan, China.
ORCID-Profile: Dong-Dong Jia, Wei-Tao Yao, Ji-Long Yang, Yong Chen, Tao Li
Zitieren
APA
Jia, D. D., Xu, Y., Ren, Z. W., Li, L. Q., Zhang, L., Li, Y., Lou, L. S., Yao, W. T., Liu, Z., Li, X. A., Yang, J. L., Chen, Y., & Li, T. (2025). Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage III Melanoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17779
Vancouver
Jia DD, Xu Y, Ren ZW, Li LQ, Zhang L, Li Y, et al. Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage III Melanoma. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17779
BibTeX
@article{Jia2025,
author = {Jia, Dong-Dong and Xu, Yu and Ren, Zhi-Wu and Li, Lin-Qing and Zhang, Lei and Li, Yang and Lou, Li-Shu and Yao, Wei-Tao and Liu, Zhe and Li, Xian-An and Yang, Ji-Long and Chen, Yong and Li, Tao},
title = {Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage III Melanoma},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17779}
}
EUVIMED